BioNTech Results Presentation Deck slide image

BioNTech Results Presentation Deck

Acquisition strengthens individualized 10 pipeline ā— Multiple individualized therapy approaches to address wide range of Solid Tumors indications. iNeST: Individualized mRNA cancer vaccine Uses patient's cancer mutations to generate neoantigen specific CD4+ and CD8+ T cell responses in vivo Early-stage / Adjuvant stage cancers 41 liO, immuno-oncology; PBMC, peripheral blood mononuclear cell; iNeST: partnered with Genentech/Roche NEOSTIM individualized neoantigen-T cell therapy Patient's PBMCs used to induce and expand multiple CD4+ and CD8+ neoantigen T cell populations ex-vivo CPI nonresponsive tumors Personalized TCR-T cell therapy Ex-vivo engineered neoantigen specific TCR-T cell therapy further strengthened by the acquistion from Kite Advanced tumors BIONTECH
View entire presentation